Christopher Lee Parks

This inventor holds 23 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Viral Vector Development. Top assignees: International Aids Vaccine Initiative, Wyeth, Wyeth Holdings Corporation. Active years: 2003-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher Lee Parks. Retrieved from https://idiyas.com/inventor/christopher-lee-parks

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 7)

% Patents Active = 87.0

CIPO Patents = 2

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 3.5

ph-index = 4

Forward Citations = 81(Granted Patents)

Location History:

Boonton, NJ (US) (2003 - 2023)
New York, NY (US) (2017 - 2024)

Company Filing History:

18 out of 71

International Aids Vaccine Initiative

Wyeth Holdings Corporation

patents

4. 1 out of 2,405

Merck Sharp + Dohme Corp.

patents

5. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...

Areas of Expertise:

SARS-CoV-2

HIV Envelope Genes

Viral Vectors

Chimeric VSV

Transgenic Cell Lines

Neutralization-resistant Mutants

Genetic Stability

Immunogenic Compositions

RNA Virus Rescue

Morbillivirus V Proteins

Broadly Neutralizing Antibodies

Viral Particles

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12311021 - Replication-competent attenuated chimeric VSV vectors encoding immunogenic SARS-CoV-2 spike proteins (2025-05-27),

2. 12305190 - Vesicular stomatitis virus and virus rescue system (2025-05-20),

3. 11891416 - Recombinant viral vectors (2024-02-06),

4. 11667930 - Vesicular stomatitis virus and virus rescue system (2023-06-06),

5. 10894080 - Transgenic VERO-CD4/CCR5 cell line (2021-01-19),

6. 10844095 - Recombinant viral vectors (2020-11-24),

7. 10792357 - Optimized HIV envelope gene and expression thereof (2020-10-06),

8. 10544430 - Vesicular stomatitis virus and virus rescue system (2020-01-28),

9. 10279027 - Transgenic Vero-CD4/CCR5 cell line (2019-05-07),

10. 10220087 - Optimized HIV envelope gene and expression thereof (2019-03-05),

11. 10202424 - Recombinant viral vectors (2019-02-12),

12. 10081796 - Neutralization-resistant CDV mutants and viral vectors (2018-09-25),

13. 9944935 - Methods to improve vector expression and genetic stability (2018-04-17),

14. 9925258 - Replication-competent VSV-HIV Env vaccines (2018-03-27),

15. 9802986 - Recombinant viral vectors (2017-10-31),

Title: The Innovative Contributions of Christopher Lee Parks

Introduction

Christopher Lee Parks, based in Boonton, New Jersey, is a distinguished inventor with a remarkable portfolio comprising 21 patents. His work primarily focuses on recombinant viral vectors, which hold significant potential in the field of vaccine development, particularly for infectious diseases such as AIDS.

Latest Patents

Parks' recent patents include groundbreaking technologies related to recombinant vesicular stomatitis viruses. These patents detail innovative methods for using these viruses as both prophylactic and therapeutic vaccines. Specifically, one patent encompasses the preparation and purification of immunogenic compositions formulated into vaccines aimed at combatting infectious diseases. This research highlights the advancement of vaccine technology and the potential for new treatments to improve global health outcomes.

Career Highlights

Throughout his career, Christopher has made substantial contributions to the field of immunology and vaccine research. He has collaborated with prominent organizations, including the International Aids Vaccine Initiative and Wyeth Holdings Corporation. His dedication to innovative research has positioned him at the forefront of vaccine development, making his insights and discoveries crucial to addressing pandemics and other infectious diseases.

Collaborations

Parks has had the opportunity to work alongside talented individuals such as Maoli Yuan and Ivo Lorenz. This collaborative spirit has fostered an environment where innovative ideas can flourish, leading to breakthroughs in the application of recombinant viral vectors for vaccines.

Conclusion

Christopher Lee Parks continues to be an influential figure in the landscape of vaccine innovation. His extensive work and numerous patents reflect a commitment to enhancing public health through cutting-edge research. As the world faces ongoing challenges related to infectious diseases, Parks' contributions remain vital for advancing medical science and ultimately protecting global health.

Profile summary based on public USPTO records.